| Name | (r)-naproxen |
|---|---|
| Synonyms |
Naproxen Impurity G
Einecs -6 piproxen (R)-Naproxen, 10 mM in DMSO (+)-(S)-Naproxen (R)-Naproxen Naproxen Impurity G (Naproxen Related Compound G, (R)-Naproxen) (R)-2-(6-Methoxy-2-naphthyl)propionic acid (R)-2-(2-methoxynaphthalen-6-yl)propanoic acid Naproxen Impurity G (R-Naproxen) Naproxen (2R)-2-(6-Methoxynaphth-2-yl)propanoic acid (R)-α-Methyl-6-methoxynaphthalene-2-acetic acid Naproxen RC G Naproxen Impurity G/ Naproxen Related Compound G (Naproxen R-Isomer) (+)-NAPROXEN ALEVE (R)-NAPROXEN (S)-naproxen Naproxen R-Isomer Naproxen Related Compound G Anaprox NAPRELAN (2S)-2-(6-Methoxynaphth-2-yl)propanoic acid (2R)-2-(6-methoxy-2-naphthyl)propanoic acid 2-Naphthaleneacetic acid, 6-methoxy-α-methyl-, (αR) (R)-()-6-Methoxy-α-methyl-2-naphthaleneacetic acid (S)-(+)-Naproxen (2R)-2-(6-Methoxynaphthalen-2-yl)propanoic Acid ((R)-Naproxen) (R)-6-METHOXY-A-METHYL-2-NAPHTHALENEACETIC ACID (R)-α-Methyl-6-methoxy-2-naphthaleneacetic acid MFCD00870716 (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid (2R)-2-(6-Methoxy-2-naphthyl)propanoic acid (r)-(-)-6-methoxy-α-methyl-2-naphthaleneacetic acid 2-Naphthaleneacetic acid, 6-methoxy-a-methyl-, (R)- (8CI) (2S)-2-(6-Methoxy-2-naphthyl)propanoic acid (R)-(-)-6-METHOXY-ALPHA-METHYL-2-NAPHTHALENEACETIC ACID Apronax EINECS 245-966-6 (R)-Naproxen, (2R)-2-(6-Methoxynaphth-2-yl)propionic acid, 2-[(1R)-1-Cboxyethyl]-6-methoxynaphthalene (S)-(+)-6-methoxy-α-methyl-2-naphthaleneacetic acid l-Naproxen (Naproxen Impurity) Naproxen Impurity 7(Naproxen Impurity G) (2R)-2-(6-methoxynaphthalen-2-yl)propanoic acid ((R)-enantiomer) 3-(4-chlorophenyl)-2-cyclohexyloxaziridine 2-Naphthaleneacetic acid, 6-methoxy-a-methyl-, - (9CI) (R)-6-methoxy-alpha-methylnaphthalene-1-acetic acid (R)-(-)-6-METHOXY-ALPHA-METHYL-2-NAPHTH& Naprosyn |
| Description | l-Naproxen ((R)-Naproxen) is an enantiomer of (S)-Naproxen. l-Naproxen can inhibit Cdc42 and Rac1 (EC50=96 μM and 212 μM, respectively), and show anti-tumor activity[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | l-Naproxen (30-1000 μM; 2 h) inhibits Rac1 and Cdc42 activity selectively in cells[3]. l-Naproxen (0-300 μM; 48 h) inhibits migration of immortalized human ovarian cancer cells[3]. l-Naproxen (300 μM; 48 h) shows activity via a COX-independent mechanism[3]. Cell Viability Assay[3] Cell Line: HeLa cells Concentration: 30-1000 μM Incubation Time: 2 hour Result: Inhibited Rac1 and Cdc42 activity in a dose dependent manner with the EC50 values of 212 μM and 96 μM, respectively. Cell Migration Assay [3] Cell Line: OvCa429 and OvCa433 cells Concentration: 0-300 μM Incubation Time: 48 hour Result: Had a statistically significant inhibitory effect at 300 μM compared to untreated controls. Western Blot Analysis[3] Cell Line: OvCa433 cells Concentration: 300 μM Incubation Time: 48 hour Result: Exhibited higher levels of phosphorylated EGFR (pEGFR) and (pERK) compared to unstimulated controls. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 403.9±20.0 °C at 760 mmHg |
| Melting Point | 156-158ºC(lit.) |
| Molecular Formula | C14H14O3 |
| Molecular Weight | 230.259 |
| Flash Point | 154.5±15.3 °C |
| Exact Mass | 230.094299 |
| PSA | 46.53000 |
| LogP | 3.00 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.609 |
| Storage condition | 2-8°C |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn |
| Risk Phrases | R22 |
| Safety Phrases | S36/S37 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3.0 |
| HS Code | 2918990090 |
| Precursor 9 | |
|---|---|
| DownStream 2 | |
| HS Code | 2918990090 |
|---|---|
| Summary | 2918990090. other carboxylic acids with additional oxygen function and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulphonated, nitrated or nitrosated derivatives. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |